In this episode of the Gaining Health podcast, host Karli Burridge gives us Part 2 of her updates from this summer!
She summarizes the findings of the cardiovascular outcome trials of semaglutide 2.4mg (Wegovy) in participants with obesity, which (spoiler alert) reduced the incidence of major adverse cardiovascular events (MACE) by 20%!!! Read the Novo Nordisk company announcement HERE
She also reviews the recent study on the effects of semaglutide 2.4 mg in patients with obesity and heart failure with preserved ejection fraction (read the article HERE) , and reviews the news release from Eli Lilly on the SURMOUNT 3 and 4 clinical trials on tirzepatide for the treatment of overweight and obesity.
While some of these studies have yet to be published by peer-reviewed journals, they do offer great hope for patients living with obesity and may offer us safe and effective tools to reduce the #1 cause of mortality: cardiovascular disease.
The Gaining Health Podcast will release a new episode monthly, every second Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.
If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer monthly and annual Memberships, which include live group coaching, a community forum to ask questions and post resources, pre-recorded Master Classes, digital resources inlcuding patient education materials and office forms, and much more!
We also sell our popular Gaining Health products, including a book on developing an obesity management program, editable forms and templates, and patient education materials in our Gaining Health Shop!
If you are loving this podcast, please consider supporting us on Patreon